Friday, October 5, 2018: 12:30 PM Background. Escherichia coli is the most common cause of community-acquired bloodstream infections. Fluoroquinolones (FQ) and trimethoprim/sulfamethoxazole (TS) are preferred for oral step-down therapy due to high bioavailability. Antimicrobial stewardship programs commonly restrict FQ use, promoting consideration of non-FQ agents for treatment of sensitive organisms. We hypothesized that oral β-lactams would be non-inferior to FQ and TS with a primary outcome of 30-day all-cause readmission.
Effect of Oral Step-Down Therapy on Readmission Rates in Escherichia coli
Background. Escherichia coli is the most common cause of community-acquired bloodstream infections. Fluoroquinolones (FQ) and trimethoprim/sulfamethoxazole (TS) are preferred for oral step-down therapy due to high bioavailability. Antimicrobial stewardship programs commonly restrict FQ use, promoting consideration of non-FQ agents for treatment of sensitive organisms. We hypothesized that oral β-lactams would be non-inferior to FQ and TS with a primary outcome of 30-day all-cause readmission.
Methods. This was a retrospective non-inferiority study that reviewed electronic health records for patients with E. coli bacteremia from January 1, 2016 to December 31, 2017. Exclusion criteria included hospital acquired infections, death during hospitalization and concomitant infections. Patient demographics, Pitt Bacteremia Score, Charleston Comorbidity Index, antibiotic regimen (IV/PO), and readmission were collected. Patients were divided into two groups, oral FQ/TS verses β-lactams. A pretrial noninferiority margin for the primary outcome was set at 3%. Secondary outcomes included 30-day infection and E. coli readmission. Significant risk factors for readmission were entered into a multiple logistic regression model in a forward stepwise approach using SPSS.
Results. Demographics were similar between groups, 57 patients received FQ/ TS and 151 received β-lactams. The 30-day-all cause readmission rate was 15.8% and 29.1%, respectively (absolute risk difference 13.3%, CI: 1-25).β-lactams were found to be inferior to FQ/TS for 30-day all-cause readmission. readmission occurred in 5.3% of patients in the FQ/TS group verses 14.6% of patients in the β-lactam group (P = 0.07). E.coli accounted for 100% of the infection-related readmissions in the FQ/ST group and 70% in the β-lactam group. Patients who received a β-lactam antibiotic were more likely to be readmitted then those patients treated with FQ/TS (odds ratio: 2.25, CI: 0.95-5.30, P = 0.06).
Conclusion.
Step-down therapy to oral β-lactams resulted in higher rates of 30-day all-cause and infection-related readmissions in patients with E. coli bacteremia.
Disclosures. All authors: No reported disclosures. Background. Edwardsiella tarda is primarily associated with gastrointestinal disease, but an increasing number of cases with extraintestinal disease have been reported. Additionally, E. tarda bacteremia (ETB) may be associated with high mortality; however, little is known about its clinical epidemiology.
Edwardsiella tarda
Methods. We collected all clinical information of ETB patients identified between January 2005 and December 2016 from their electronic medical records. We described the epidemiology, clinical features, and 30-and 90-day mortality of these patients.
Results. A total of 182,668 sets of blood cultures were obtained during the study period, of which 40 sets (0.02%) taken from 26 patients were E. tarda positive.
Twenty-six patients (13 men and 13 women) with a median age of 75 years were diagnosed with ETB. Clinical diagnoses by infection site included cholangitis (n = 9), liver abscess (n = 6), enterocolitis (n = 4), cholecystitis (n = 3), and spontaneous bacterial peritonitis, mycotic aneurysm, necrotizing fasciitis, empyema, osteomyelitis, and secondary peritonitis (n = 1 each). The overall 30-day and 90-day mortality rates of ETB in our cohort was 11.5% (3/26) and 26.9% (7/26), respectively. There was no seasonal variation in the incidence of E. tarda infection. All E. tarda strains isolated from blood cultures were susceptible to all tested antibiotics. Additionally, hepatobiliary infection was more frequently seen in ETB compared with non-bacteremic E. tarda infections.
Conclusion. This study is the largest case series on ETB to date. We found that ETB is a rare entity that is not associated with high mortality. Hepatobiliary infection is the most common clinical manifestation.
Disclosures. All authors: No reported disclosures. Background. Prior studies have suggested that surveillance blood cultures (SBCs) may not be indicated in the setting of Gram-negative bacteremia (GNB). However, it is unclear how particular microbial species influence the need for SBCs in GNB.
Surveillance Blood Cultures Associated With Decreased Mortality in Gram-
Methods. We conducted a prospective cohort study of inpatients at Duke with Staphylococcus aureus bacteremia (SAB) and GNB from 2002-2015. Patients who died <24 hours from the first positive blood culture were excluded. Patients provided written informed consent. SBCs were defined as a blood culture drawn from 24 hours to 7 days from initial positive blood culture. Persistent bacteremia was defined as a positive SBC with the same organism. Statistical testing included Fishers exact and chi-square tests.
Results. There were 2856 episodes of bacteremia over the study period Conclusion. Acquisition of SBCs in patients with GNB was associated with decreased mortality, and this was driven in part by species-specific differences.
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